Severine Guiu
Overview
Explore the profile of Severine Guiu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jacot W, Chateau M, Thezenas S, Guiu S, Firmin N, Lafont V, et al.
Cancer Med
. 2025 Mar;
14(5):e70615.
PMID: 40059728
Introduction: Triple-Negative Breast Cancer (TNBC) is an aggressive breast cancer subtype, in which targeting the Trophoblast cell-surface antigen-2 (Trop-2), using antibody-drug conjugates (ADC), results in significant clinical improvement. However, clinicopathological...
2.
Bottosso M, Griguolo G, Guiu S, Guarascio M, Bailleux C, Miglietta F, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):20.
PMID: 39979277
Brain metastases (BMs) are a common complication of advanced breast cancer (BC), and their management has significantly evolved. We evaluated the clinical impact of these changes dividing patients diagnosed with...
3.
Bonnefoi H, Lerebours F, Pulido M, Arnedos M, Tredan O, Dalenc F, et al.
Lancet Oncol
. 2025 Feb;
26(3):355-366.
PMID: 39978376
Background: We proposed in 2005 that androgens replace oestrogens as the driver steroids in a subgroup of triple-negative breast cancer (TNBC) with androgen receptor (AR) expression called molecular apocrine (MA)...
4.
David T, du Roure P, Mallavialle A, Laurent-Matha V, Roger P, Guiu S, et al.
Br J Pharmacol
. 2025 Jan;
182(8):1671-1682.
PMID: 39834229
Cathepsins, the most abundant lysosomal proteases, have key functions in cell maintenance and homeostasis. They are overexpressed and hypersecreted in cancer and associated with poor prognosis. Secreted cathepsins display pro-tumour...
5.
du Roure P, David T, Mallavialle A, Laurent-Matha V, Roger P, Guiu S, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39800383
Triple-negative breast cancer (TNBC) is a heterogeneous breast cancer subtype characterized by aggressive clinical behavior and poor prognosis. The immune landscape associated with TNBC often reveals high immunogenicity. Therefore, immunotherapy,...
6.
Boissiere-Michot F, Chateau M, Thezenas S, Lafont V, Crapez E, Sharma P, et al.
Front Immunol
. 2024 Dec;
15:1507371.
PMID: 39723208
Background: In triple-negative breast cancer (TNBC), the most immunogenic breast cancer type, tumor-infiltrating lymphocytes (TILs) are an independent prognostic factor. Tertiary lymphoid structures (TLS) are an important TILs source, but...
7.
Massa D, Vernieri C, Nicole L, Criscitiello C, Boissiere-Michot F, Guiu S, et al.
J Natl Cancer Inst
. 2024 Jul;
116(12):1914-1927.
PMID: 39083015
Background: The cutoff of <1% positive cells to define estrogen receptor (ER) negativity by immunohistochemistry (IHC) in breast cancer (BC) is debated. We explored the tumor immune microenvironment and gene-expression...
8.
Meunier L, De Martin E, Delire B, Jacot W, Guiu S, Zahhaf A, et al.
JHEP Rep
. 2024 Jul;
6(7):101098.
PMID: 38961854
Background & Aims: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are the cornerstone of systemic therapy for patients with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer. In the various therapeutic studies with...
9.
Frenel J, Zeghondy J, Guerin-Charbonnel C, Mailliez A, Volant E, Poumeaud F, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e244435.
PMID: 38568692
Importance: Little is known regarding the outcomes associated with tucatinib combined with trastuzumab and capecitabine (TTC) after trastuzumab-deruxtecan exposure among patients with ERBB2 (previously HER2)-positive metastatic breast cancer (MBC). Objective:...
10.
du Roure P, Lajoie L, Mallavialle A, Alcaraz L, Mansouri H, Fenou L, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38290768
Introduction: Triple-negative breast cancer (TNBC) prognosis is poor. Immunotherapies to enhance the antibody-induced natural killer (NK) cell antitumor activity are emerging for TNBC that is frequently immunogenic. The aspartic protease...